











S90Long-Term Consequences of Hematopoietic Stem Cell
Transplantation: Current State of the Science
K. Scott Baker,1 Saro Armenian,2 Smita Bhatia2Hematopoietic cell transplantation (HCT) is an
established curative option for a variety of hematologic
malignancies. Liberalization in the indications for trans-
plantation coupled with an increase in options in the
source of the hematopoietic stem cells (HSCs) are re-
sponsible for the increasingnumberofHCTsperformed
annually [1]. Advances in transplantation techniques and
supportive care strategies have resulted in a significant
improvement in survival, such that long-term survival
has now become an expected outcome for patients
undergoingHCT.However, exposure to chemotherapy
prior to transplantation as well as at the time of trans-
plantation, coupled with prolonged periods of immune
suppression and the risk of disease recurrence, place
thispopulationatan increased riskof chronichealth con-
ditions, suchas cardiaccompromise, endocrine sequelae,
and subsequent malignancies. Furthermore, premature
death remains of significant concern among health care
providers as well as patients who have successfully
survived the immediate post-HCT period. The follow-
ing sections will focus on long-term survival and causes
of premature death among patients undergoing HCT;
on the overall burden of morbidity suffered by long-
term survivors, with special emphasis on the occurrence
of metabolic syndrome in this population and its impact
on cardiac dysfunction and the need to understand indi-
vidual variability in the risk for post-HCT complica-
tions, as we move closer to personalized medicine.LONG-TERM SURVIVAL AND PREMATURE
DEATH
Long-term survival and premature deaths after al-
logeneic HCT were first examined for 6691 patients1Fred Hutchinson Cancer Research Center, Seattle,
ington; and 2City of Hope National Medical Center,
e, California.
isclosure: See Acknowledgments on page S94.
dence and reprint requests: K. Scott Baker, MD, MS,
Hutchinson Cancer Research Center, 1100 Fairview
e Norht, Mailstop D5-280, Seattle, WA 98109 (e-mail:
er@fhere.org).
erican Society for Blood and Marrow Transplantation
/10/161S-0016$36.00/0
6/j.bbmt.2009.09.017registered with the International BoneMarrow Trans-
plant Registry (IBMTR) [2]. This study reported the
overall survival (OS) for those who were disease-free
for 2 or more years after allogeneic HCT to be 89%
at 5 years. The risk of death after 5 years approached
that of the general population for patients with severe
aplastic anemia (SAA). Recurrent disease was the chief
cause of premature death. However, registry studies
such as this are limited by the dependence on passive
reporting of events by the participating institutions.
This limitation was overcome by the Bone Marrow
Transplant Survivor Study (BMTSS), where a compre-
hensive evaluation of cause-specific late mortality was
performed in patients treated with HCT by using
central resources such as the National Death Index
or Social Security Death Index, supplemented by in-
formation abstracted from medical records. Late mor-
tality was evaluated in 1479 individuals who had
survived 2 or more years after allogeneic HCT [3].
Median age at HCT was 25.9 years and the median
length of follow-up was 9.5 years. The conditional sur-
vival probability at 15 years from HCT was 80.2% 6
1.9% for those who were disease-free at entry into
the cohort, and the cohort was at a 9.9-fold increased
risk of premature death compared with the general
population. Relative mortality decreased with time
from HCT, but remained significantly elevated at 15
years after HCT (standardized mortality ratio [SMR]
5 2.2). Relapse of primary disease and chronic graft-
versus-host disease (cGVHD) were the leading causes
of premature death. Late mortality in 854 individuals
who had survived 2 or more years after autologous
HCT for hematologic malignancies was also assessed
in the BMTSS cohort [4]. Median age at HCT was
36.5 years and median length of follow-up was 7.6
years. OS was 68.8% 6 1.8% at 10 years, and the
cohort was at a 13-fold increased risk for premature
death when compared with the general population.
Mortality rates approached those of the general popu-
lation after 10 years among patients at standard risk for
relapse at HCT and in patients undergoing HCT for
acute myelogenous leukemia (AML). Relapse of
primary disease and subsequent malignancies were
leading causes of premature death. Relapse-related
mortality was increased among patients with Hodgkin
lymphoma (HL), non-Hodgkin lymphoma (NHL),
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irradiation (TBI) provided a protective effect.Table 1. ATP III Criteria for Metabolic Syndrome—Indicated
by 3 or More Positive Findings
Criterion Adults Adolescents*
High Triglyceride Level, mg/dL $150 $110





Males >102 $90th Percentile
Females >88 $90th Percentile
High fasting glucose level, mg/dL $100† $100†
High blood pressure, mmHg $130/85 $90th Percentile
*ATP III criteria modification for adolescents (aged 12–19 years) as
described by Cook et al [24].
†American Diabetes Association 2003 definition lowers abnormal
fasting glucose level to 100 mg/dL [73] and this change has been incor-
porated into the current definition of metabolic syndrome [74].BURDEN OF MORBIDITY
Control of the underlying disease and prolonga-
tion of life among HCT survivors is not necessarily
accompanied by full restoration of health. HCT survi-
vors are at risk for long-term treatment-related com-
plications, such as endocrinopathies, musculoskeletal
disorders, cardiopulmonary compromise, and subse-
quent malignancies [5-15]. Understanding the burden
of morbidity because of these treatment-related com-
plications is important to the health care providers
and policy makers in identifying and procuring re-
sources for the long-term care of individuals with
a high burden of morbidity, to the researchers in iden-
tifying common etiologic pathways that lead to the
overall morbidity, and to theHCT survivors inmaking
an informed decision regarding the quality-of-life con-
cerns long-term after HCT.
The burden of morbidity because of chronic health
conditions was evaluated in HCT survivors and
a healthy sibling comparison group participating in
the BMTSS [16]. HCT survivors and siblings com-
pleted a 255-item questionnaire, which covers the fol-
lowing general areas: diagnosis of physical health
conditions with age at diagnosis (endocrinopathies;
central nervous system compromise; cardiopulmonary
dysfunction; gastrointestinal and hepatic sequelae;
musculoskeletal abnormalities; and subsequent malig-
nancies); diagnosis and extent of cGVHD; access to
and use of medical care; and sociodemographic char-
acteristics (education, marital status, employment,
household income, and insurance). The reliability
and validity of the BMTSS questionnaire has been
tested, and the responses have demonstrated a high
level of sensitivity and specificity, confirming that sur-
vivors are able to report the occurrence of adverse
medical conditions with accuracy [17]. The prevalence
and severity of chronic health conditions reported by
individuals who had undergone HCT between 1976
and 1998 and survived 2 years (n 5 1022), and their
siblings (n 5 309) is described here. A severity score
(grades 1 [mild] through 4 [life-threatening]) was as-
signed to each health condition using the Common
Terminology Criteria for Adverse Events (version 3).
The mean age at enrollment was 43.1 years and 44.8
years for survivors and siblings, respectively. Among
HCT survivors, 66% had at least 1 chronic condition,
and 18% had a severe or life-threatening condition;
comparable figures in siblings were 39% and 8%, re-
spectively (P\ .001). HCT survivors were 3.5 times
more likely to develop severe/life-threatening condi-
tions (95% confidence interval [CI], 2.3-5.4), when
compared with age- and sex-matched siblings. Theprevalence of any chronic health condition was signif-
icantly higher among allogeneic HCT recipients when
compared with autologous HCT recipients (any
chronic health conditions: 71.1% versus 60.7%, P 5
.001; grade 3 or 4 conditions: 20.6% versus 15.5%,
P5 .04). The cumulative incidence of a chronic health
condition among patients, who had survived the first 2
years after HCT was 32% (95% CI, 30%-35%) and
59% (95% CI, 56%-62%) at 2 and 10 years after
HCT, respectively. HCT survivors are more likely to
report difficulty in holding jobs (allogeneic HCT sur-
vivors report a 14-fold increased risk compared with
the siblings, whereas autologous HCT recipients re-
port a 9-fold increase risk). Furthermore, HCT survi-
vors report greater difficulty in obtaining health
insurance (7-fold greater difficulty) or life insurance
(9-fold greater difficulty) compared with the sibling
comparison group [3,4].
BMTSS data reveals that long-term survivors of
HCT are at a 2.9-fold increased risk of reporting se-
vere or life-threatening cardiovascular disease when
compared with age- and sex-matched siblings [16].
Furthermore, female recipients of autologous HCT
are at a 4.4-fold increased risk of premature death
from cardiac causes when compared with age-matched
general population [4]. The next few sections focus on
the magnitude of risk and pathogenetic risk factors for
the development of cardiovascular complications in
HCT survivors.METABOLIC SYNDROME AFTER HCT
Metabolic syndrome is a constellation of central
obesity, insulin resistance, glucose intolerance, dyslipi-
demia, and hypertension, and is associated with a sub-
stantially increased risk for type 2 diabetes mellitus and
atherosclerotic cardiovascular disease (CVD) [18-20].
Data from the third National Cholesterol Education
Program Adult Treatment Panel III (NHANES)
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metabolic syndrome in the U.S. population of adults is
21.7%, with little difference by sex. A comparative
analysis of NHANES III with NHANES 1999 to
2000 has shown that the age adjusted prevalence of
metabolic syndrome in the United States has increased
from 24.1% in to 26.7% (P 5 .088) [23].
The BMTSS demonstrated that, after adjustment
for age, sex, and body mass index (BMI), allogeneic
HCT survivors were 3.7 times (95% CI: 1.8-7.3)
more likely to report diabetes and 2.1 times (95% CI:
1.4-3.0) more likely to report hypertension compared
to siblings. Allogeneic HCT survivors were also more
2.3 times more likely to report hypertension (95%
CI: 1.5-3.7) when compared with autologous recipi-
ents; finally, TBI was associated with an increased risk
of diabetes (odds ratio [OR]5 3.4, 95% CI: 1.6-7.5).
In the adolescent population in the United States,
the prevalence of metabolic syndrome (Table 1) was
4.2% (6.1% in males and 2.1% in females) [24], with
an increase to 6.8% per the NHANES 1999-2000
(P5 .02) [25]. More importantly, nearly 30% of over-
weight adolescents meet the criteria for metabolic
syndrome. There is preliminary evidence to suggest
that childhood cancer survivors are at an increased
risk for premature development of metabolic syn-
drome [26-28]. In adult survivors of childhood ALL,
various factors, including female sex [29], genetic pre-
disposition [30], exposure to steroids [31], and cranial
radiation therapy [29,32], have been implicated in the
development of obesity and other conditions charac-
teristic of metabolic syndrome. The Childhood Can-
cer Survivor Study (CCSS) reports that childhood
cancer survivors who have received .20 Gy of cranial
radiation are 2.6-fold (females) and 1.9-fold (males)
more likely to be obese, when compared with age-
and race-matched siblings. The risk for obesity is
greatest among females exposed to radiation exceed-
ing 20 Gy at 0 to 4 years of age [29]. Although the
total dose of TBI exposure in HCT protocols is
typically in the range of 10 to 14 Gy, the dose rate is
higher, which may have a greater impact at the cellular
level than a higher dose given over a longer time
period [33].
In addition to significantly higher weight and body
fat, childhood cancer survivors have been shown to
have higher fasting plasma glucose and insulin levels,
and lower serum high density lipoprotein (HDL) cho-
lesterol [26]. A combination of obesity, hyperinsuline-
mia, and low HDL cholesterol was seen in 16% of
the survivors, but in none of the controls (P 5 .01).
Of the survivors with indicators of metabolic syn-
drome, 50% had received cranial radiation, and also
had markedly reduced spontaneous growth hormone
(GH) secretion. Similar results were found in survivors
of allogeneic HCT performed in childhood. Hyperin-
sulinemia, impaired glucose tolerance (by oral glucosetolerance test), hypertriglyceridemia, low HDL
cholesterol, and abdominal obesity were more com-
mon among the HCT patients than among either the
non-HCT group of leukemia patients or healthy con-
trols [34]. Core signs of metabolic syndrome were
found in 39% ofHCT survivors versus 8% of leukemia
controls and 0% of healthy controls. Fifty-two percent
of HCT patients were found to have hyperinsulinemia
and 43%had abnormal glucosemetabolism, compared
to none of the healthy controls (P 5 .0002, and .001
respectively). Variables associated with hyperinsuline-
mia in the HCT patients were time from transplanta-
tion (P 5 .01), presence of cGVHD (P 5 .01), and
hypogonadism (P 5 .04). Another study found that
the patients who received TBI had a significantly
higher first phase insulin response and insulinemia/
glycemia ratio on glucose tolerance testing compared
to patients who received only lymphoid radiation, no
radiation, or controls [35], suggesting that TBI may
play a role in the development of insulin resistance.
Presence of metabolic syndrome places survivors
at an elevated risk for a number of adverse health out-
comes, such as overt diabetes and cardiovascular dis-
ease, which when combined with prior exposure to
cardiotoxic agents such as chest radiation and anthra-
cyclines and cyclophosphamide (Cy) [36,37] could
have a potentially devastating consequence on the sur-
vivors [28]. Preclinical and clinical evidence of the im-
pact of the components of metabolic syndrome on
radiation-related atherosclerotic heart disease and an-
thracycline-related congestive heart failure is de-
scribed in detail in the following section.CARDIOVASCULAR EFFECTSOFMETABOLIC
SYNDROME
Atherosclerosis is a complex process involving in-
flammation and cellular proliferation in arterial walls.
The development and progression of atherosclerosis
is mediated by a variety of growth factors, cytokines,
thrombotic factors, and vasoactive substances. Insulin
resistance is a suspected causal pathway because of its
clinical association with increased rates of macrovascu-
lar disease and subsequent cardiovascular morbidity
and mortality [38]. Insulin resistance is associated
with endothelial dysfunction and impaired insulin-
mediated nitric oxide-dependent vasodilation [39]. En-
dothelial dysfunction occurs early in the pathogenesis
of atherosclerosis and is associated with many cardio-
vascular pathologic disease states. Strong evidence ex-
ists showing the association between arterial stiffness
and atherosclerosis, cardiovascular disease, and mor-
tality [40,41]. Radiation therapy, including TBI, may
lead to arterial stiffness and, therefore, potentially to
atherosclerosis. In an ongoing study we have measured
insulin resistance, fasting glucose, insulin, lipids,
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compliance and distensibility in 106 survivors of
HCT performed in childhood (current age 26.6 years)
and 72 healthy sibling controls (current age 23.7 years).
Preliminary analysis found 2 or more components of
metabolic syndrome were present in 37% survivors
and only 13.9% controls (OR, 2.7, 95% CI 1.2-5.9, P
5 .02). HCT survivors who had TBI with or without
cranial radiation had significantly higher total choles-
terol, LDL cholesterol, triglycerides, and insulin, and
lower HDL cholesterol levels, and they were also
more insulin resistant. However, for the subjects who
did not receive any radiation prior to or during HCT,
there were no differences in any of the cardiovascular
risk factors compared to controls. Carotid artery dis-
tensibility was decreased in survivors who received
TBI compared to controls with an even greater nega-
tive impact in those who received TBI and pre-HCT
cranial radiation. These findings are concerning, and
suggest that even at a relatively young age, and inde-
pendent of obesity,HCTsurvivors of childhood hema-
tologicmalignancies have increased cardiovascular risk
factors present as well as adverse vascular changes,
which are associated with exposure to TBI, with or
without cranial radiation. These abnormalities may
ultimately contribute to a higher risk of early cardiovas-
cular morbidity andmortality, and thus early screening
and management of modifiable cardiovascular risk fac-
tors should be considered in HCT survivors.ANTHRACYCLINE-RELATED CONGESTIVE
HEART FAILURE (CHF) AFTER HCT
CHF is a well-described sequela during the imme-
diate post-HCT period. Mortality attributed early
CHF ranges from1% to 9%,whereasmorbidity ranges
from5%to43% [42-44].Risk factors for earlyCHF in-
clude reduced pre-HCT ejection fraction (EF), condi-
tioning with high-dose (HD) Cy andTBI [44-46]. The
occurrence of CHF after the first year (late CHF) is less
well studied, with few reports describing this outcome
hampered by relatively short lengths of follow-up and
small sample size [47,48]. Potential mediators of late
CHF include pretransplantation exposure to known
cardiotoxic agents such as anthracyclines, alkylating
agents, and mediastinal radiation, compounded by
HD Cy and TBI at the time of HCT and the presence
of GVHD after HCT [49,50]. Furthermore, the mag-
nitude of risk could be moderated by the presence of
comorbid conditions and host characteristics such as
age at exposure and sex of recipient [49].
We recently examined the independent role of pre-
HCTexposure to therapeutic agents, transplant-related
conditioning, and comorbidities in the development of
late CHF after HCT [51]. Using a nested case control
design, we identified cases with late CHF from a cohortof nearly 3000 11 year survivors who underwentHCT.
Median age atCHFdiagnosis was 51 years (range: 22.5-
71 years), and median time from HCT was 3 years
(range: 1-19 years); all had clinical CHF per the Amer-
ican Heart Association (AHA)/American College of
Cardiology (ACC) guidelines [52]. We found pre-
HCT exposure to anthracyclines and presence of
post-HCT comorbidities to be primarily responsible
for the risk of late CHF after HCT, whereas condition-
ing-related exposures did not appear to contribute
significantly to the risk. The cardiotoxic effect of an-
thracyclines was highest for autologous HCT recipi-
ents, with a cumulative dose of $250 mg/m2 being
associated with a 30-fold increased risk of late CHF.
OS was\50% at 2 years after CHF diagnosis.ROLE OF GENETIC SUSCEPTIBILITY
IN THE DEVELOPMENTOF CARDIAC
COMPLICATIONS AFTER HCT
It is becoming increasingly recognized that risks
for many diseases result from an interaction between
inherited gene variants and environmental factors, in-
cluding chemical, physical, and behavioral factors.
However, there continue to be large gaps in knowledge
with regard to the pathogenesis of therapy-related
adverse events. These gaps can be filled only by
approaching these problems in a systematic, compre-
hensive manner that not only helps further the under-
standing of disease biology, but also identifies those at
highest risk of these adverse outcomes, raising the pos-
sibility of targeted disease prevention and health pro-
motion efforts for individuals at high risk because of
their genetic makeup.
Recent advances in the sequencing of the human
genome [53,54] have created many opportunities for
investigating the relationship between polymorphic
genetic variants present in the human population and
their impact on the pathogenesis of various medical
conditions [55-57]. The traditional approach has
been to use the candidate gene approach, in which
a gene or pathway is targeted as potentially important
based on a priori hypotheses about their etiologic role
in development of disease [58]. However, the sequenc-
ing of the human genome has greatly expanded the
ability of researchers to broaden the focus of genomic
studies and perform genome-wide association studies
(GWAS), allowing the study of genetic variation across
the entire genome and risk of disease [59]. Here we
present the example of anthracycline-related conges-
tive heart failure (A-CHF) to demonstrate how genet-
ics could potentially play a role in explaining the
observed interindividual variability in risk of develop-
ing A-CHF.
A-CHF is thought to be related to direct myocar-
dial injury because of the formation of free radicals
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include female sex, younger age at exposure, and radi-
ation therapy involving the heart [61-63]. However,
these clinical risk factors do not fully explain the
wide interindividual variability in susceptibility to
A-CHF. Significant cardiotoxicity has been reported
at cumulative doses of\250mg/m2[64], whereas doses
that exceed 1000 mg/m2 have been tolerated without
long-term sequelae by some [65]. Among long-term
HCT survivors [51], 40% of cases with clinical CHF
had received a cumulative dose of\250 mg/m2.This
heterogeneity could be explained, in part, by genetic
susceptibility that alter the metabolism of anthracy-
clines, the myocardial response to the drug, as well as
others thought to play a role in susceptibility to de
novo disease [66-68].
The strongest support for the role of these genes as
regulators of response to anthracyclines has come from
transgenic and knock-out mouse strains with altered
sensitivity to the drugs. For example, transgenic overex-
pression of themultiple drug resistance gene (MDR1) is
protective against the cardiotoxic effect of anthracy-
clines [69], whereas deficiency and overexpression of
anthracyclinemetabolizing enzyme, carbonyl reductase
(CBR) inmice had opposing effects (protecting and en-
hancing) on susceptibility to A-CHF [66,70,71]. A
limitation of information obtained from such geneti-
cally engineered mouse strains is the strong penetrance
of introduced mutations, which likely does not reflect
more subtle genetic variability in humans [67].
Two recent studies in humans have evaluated the
role that these genetic alterations play in the develop-
ment of clinical A-CHF. These studies suggest that
polymorphisms in genes involved in anthracycline me-
tabolism, transport, and superoxide generation may
have an impact on an individual’s risk of A-CHF. In
the first study [68], 82 genes involved in the metabo-
lism of reactive oxygen species (ROS), DNA repair,
drug transport, and metabolism, endothelial physiol-
ogy, the renin-angiotensin system, muscle contraction
and structure, and inflammation were evaluated. The
risk of chronic cardiotoxicity was significantly in-
creased (OR5 2.5) in individuals with a polymorphism
for the NADPH oxidase subunit, NCF4, which is re-
sponsible for downregulation of the enzyme involved
in a multienzyme complex regulating ROS generation.
Inherited NADPH oxidase deficiency may result in
impaired ROS defense capacity, and therefore lead to
increased intracardiac ROS levels after anthracycline
exposure [68].
The second study [66] examined polymorphisms in
genes such as: catalase (CAT), superoxide dismutase 1
(SOD1), NADPH:quinone oxidoreductase (NQO1),
and carbonyl reductase 3 (CBR3). A polymorphism in
CBR3 (V244M) was associated with a markedly in-
creased risk of A-CHFamong homozygous and hetero-
zygous individuals (OR5 8.2 and5.4, respectively). It isbelieved that the functional CBR3 polymorphism may
modulate intracardiac formation of cardiotoxic anthra-
cycline alcohol metabolites, leading to myocardial in-
jury and eventual cardiac dysfunction. These 2 studies
illustrate how certain ‘‘at-risk’’ alleles in key candidate
genes could identify individuals at the highest risk of de-
veloping anthracycline-related cardiotoxicity. If these
findings are replicated and confirmed by others in inde-
pendent study samples, they could set the stage for iden-
tifying a subgroup of patients up front who would
perhaps need alternative treatment for management of
their cancer; whereas for those who have already
received the anthracyclines, identification of high-risk
alleles would warrant closer surveillance for cardiotox-
icity and use of medications that modulate cardiac
function.
The data presented here demonstrates that HCT
survivors have a high burden of morbidity, especially
as it relates to development of cardiovascular disease,
and that attention needs to focus on instituting system-
atic and targeted follow-up of those at high risk [72].ACKNOWLEDGMENTS
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